Skip to main content
. 2020 Apr 29;34(4):555–568. doi: 10.1007/s10557-020-06981-3

Fig. 4.

Fig. 4

Event rates (a) and hazard ratios (or relative risk for dabigatran) (b) for intracranial haemorrhage in patients ≥ 75 years of age in the four trials comparing non-vitamin K oral anticoagulants to vitamin K antagonist for stroke prevention in atrial fibrillation. HR, hazard ratio; NOAC, non-vitamin K oral anticoagulants; RR, relative risk; VKA, vitamin K antagonist. Dosing regimens are given for all studies in Table 1